Top Psychedelic Stocks 2026
Financial disclaimer
This article is for informational purposes only and is not financial advice, investment advice or a recommendation to buy or sell any security.
The leading publicly traded psychedelic companies in 2026 include Compass Pathways, Definium Therapeutics, AtaiBeckley, Helus Pharma and GH Research. Compass offers the clearest late-stage psilocybin exposure after both of its pivotal Phase 3 studies met their primary endpoints. The wider public group covers LSD, DMT, mebufotenin, MDMA, natural psilocybin, legal truffles and non-hallucinogenic neuroplastogens. You should treat each category as a different investment case with its own clinical, regulatory, financing and liquidity risks.
Here, top refers to clinical maturity, direct psychedelic exposure and the availability of recent public data. It does not predict share-price performance. This maintained list omits live prices and market values because both age quickly.
Psychedelic Stocks List 2026
| Rank | Company | Main listing | Primary exposure | Current status | Psilocybin link |
|---|---|---|---|---|---|
| 1 | Compass Pathways | Nasdaq CMPS | Synthetic psilocybin | Two positive Phase 3 primary endpoints, rolling NDA underway | Direct |
| 2 | Definium Therapeutics, formerly MindMed | Nasdaq DFTX | Lysergide, or LSD | Positive Phase 3 MDD study, other Phase 3 studies active | None |
| 3 | AtaiBeckley | Nasdaq ATAI | Mebufotenin, DMT and R-MDMA | BPL-003 in Phase 3, VLS-01 in Phase 2b | None |
| 4 | Helus Pharma, formerly Cybin | Nasdaq HELP | Deuterated serotonergic agonists | HLP003 in Phase 3 for MDD | Related to psilocin |
| 5 | GH Research | Nasdaq GHRS | Inhaled mebufotenin | Positive Phase 2b TRD study, US clinical hold lifted | None |
| 6 | Incannex Healthcare | Nasdaq IXHL | Synthetic psilocybin | Positive Phase 2 GAD data, next-phase planning | Direct |
| 7 | Psyence Biomedical | Nasdaq PBM | Nature-derived psilocybin and ibogaine | NPX-5 Phase 2b study active | Direct |
| 8 | Optimi Health | Nasdaq OPTH and CSE OPTI | Natural psilocybin and MDMA manufacturing | Commercial supply and clinical-trial shipments | Direct |
| 9 | Red Light Holland | CSE TRIP and OTCQB TRUFF | Natural psilocybin truffles and botanical drug supply | Legal Dutch sales, Filament Health acquired | Direct |
| 10 | Bright Minds Biosciences | Nasdaq DRUG and CSE DRUG | Selective serotonin drugs | Positive Phase 2 BMB-101 data | None |
| 11 | Clearmind Medicine | Nasdaq CMND | MEAI-based treatment | Phase 1 and 2a safety endpoint met | None |
| 12 | Enveric Biosciences | Nasdaq ENVB | Non-hallucinogenic neuroplastogens | EB-003 in preclinical and IND-enabling work | None |
| 13 | PharmAla Biotech | CSE MDMA and OTCQB MDXXF | MDMA and MDXX compounds | Clinical supply and drug development | None |
The table includes research-stage issuers, commercial suppliers and companies selling legal truffles. Those business models do not carry the same type of exposure. A clinical-stage biotech may rise or fall on one trial. A supplier depends on regulated demand, manufacturing quality and customer orders. A legal consumer operator depends on jurisdiction-specific rules and retail execution.
1. Compass Pathways
Compass Pathways ranks first for direct psilocybin exposure and clinical maturity. Its lead candidate, COMP360, is a proprietary synthetic psilocybin formulation studied for treatment-resistant depression.
COMP005 met its Phase 3 primary endpoint in June 2025. COMP006 met its Phase 3 primary endpoint in February 2026. In the second study, two 25 mg doses produced a 3.8-point placebo-adjusted difference on the Montgomery-Asberg Depression Rating Scale at week six. Compass then reported 26-week COMP006 data in July 2026 and said its rolling New Drug Application submission was underway, with final submission planned for the fourth quarter of 2026. Compass reported the two Phase 3 endpoints and its current filing status in official releases.
For your research, separate positive trial results from regulatory approval. COMP360 remains investigational. The Food and Drug Administration still needs to review the full application, manufacturing package, safety data and proposed treatment model. Commercial use would also depend on controlled-substance scheduling, treatment-site readiness, reimbursement and trained staff.
2. Definium Therapeutics
Definium Therapeutics is the current name of Mind Medicine, or MindMed. The company changed its Nasdaq ticker from MNMD to DFTX in January 2026. Any psychedelic stocks list 2026 that still presents MNMD as the active symbol is stale. Definium confirmed the name and ticker change in January 2026.
Its lead candidate, DT120 ODT, is a pharmaceutical form of lysergide, commonly called LSD. In June 2026, the Emerge Phase 3 study in major depressive disorder met its primary endpoint and all key secondary efficacy endpoints. The placebo-adjusted change on the depression scale was 8.1 points at week six. Definium also has active Phase 3 work in generalized anxiety disorder and a second major-depression study. The Emerge release provides the trial design, result and safety overview.
Definium gives you late-stage classic psychedelic exposure without direct psilocybin exposure. Its investment case depends heavily on repeatability across Phase 3 studies, the regulatory package for DT120 and the operating demands of a long supervised dosing session.
3. AtaiBeckley
AtaiBeckley was formed when atai Life Sciences and Beckley Psytech combined in November 2025. The company retained the Nasdaq symbol ATAI. Its portfolio gives you exposure to several psychedelic compounds and delivery formats.
The lead program is BPL-003, an intranasal formulation of mebufotenin benzoate, also called 5-MeO-DMT. BPL-003 has Food and Drug Administration Breakthrough Therapy designation and is in Phase 3 development for treatment-resistant depression. VLS-01 is a DMT film used inside the cheek and completed dosing in a Phase 2b study in July 2026. EMP-01 is an oral R-MDMA program in Phase 2 development. AtaiBeckley reported the current stages and July 2026 VLS-01 milestone.
You gain a broader pipeline than you would with a single-asset issuer, yet BPL-003 remains the main late-stage value driver. AtaiBeckley has no direct psilocybin program in the table, so it fits the wider psychedelic stock category.
4. Helus Pharma
Helus Pharma is the operating name adopted by Cybin in January 2026. Its shares moved from NYSE American under CYBN to Nasdaq under HELP. The old CYBN ticker should no longer appear as the active US symbol. The company disclosed the exchange transfer and HELP ticker in its filing.
HLP003, previously known through the CYB003 program, is a deuterated serotonergic agonist in Phase 3 development as an adjunctive treatment for major depressive disorder. The company lists Phase 3 APPROACH data for the fourth quarter of 2026. HLP004 is an intramuscular deuterated serotonergic agonist studied for generalized anxiety disorder. Helus lists both clinical programs and their current stages on its development page.
For a psilocybin-focused screen, classify HELP as related exposure. HLP003 is linked chemically to psilocin. The company now describes its platform as serotonergic agonist drug development.
5. GH Research
GH Research develops GH001, an inhaled formulation of mebufotenin, or 5-MeO-DMT, for treatment-resistant depression. Its randomized Phase 2b study met the primary endpoint in 2025. In January 2026, the Food and Drug Administration lifted the clinical hold on GH001, clearing US clinical investigation. The Phase 2b results were published in JAMA Psychiatry in March 2026. GH Research reported the peer-reviewed publication and trial status.
The short acute drug experience is central to the company’s proposed care model. You still need to examine the design of the pivotal program, repeat-dosing plan, monitoring requirements and regulatory discussions. Positive Phase 2b data reduces one form of clinical uncertainty. Phase 3 and approval risk remain.
6. Incannex Healthcare
Incannex Healthcare offers direct synthetic psilocybin exposure through PSX-001, previously called Psi-GAD. A 73-participant Phase 2 study tested two 25 mg psilocybin sessions with psychological support in generalized anxiety disorder. The company reported a statistically significant primary endpoint in 2025 and entered 2026 with next-phase clinical and regulatory planning underway. The January 2026 filing records the program status and planned next steps.
PSX-001 is one program inside a broader pipeline that also includes non-psychedelic drug candidates. Your review should account for capital allocation across the full company, since the share price does not track psilocybin alone.
7. Psyence Biomedical
Psyence Biomedical is one of the few Nasdaq-listed companies centered on nature-derived psilocybin. NPX-5 is being studied with psychotherapy for adjustment disorder in palliative care. The company began patient dosing in its Phase 2b study in April 2026, with a planned enrollment of about 87 participants. Psyence describes the active Phase 2b study and 2026 timetable on its clinical page.
This is direct natural-psilocybin biotech exposure. The program remains earlier than Compass and addresses a different patient group. You should assess enrollment pace, trial endpoints, manufacturing controls, cash use and access to new capital.
8. Optimi Health
Optimi Health manufactures finished-dose natural psilocybin and MDMA products under a Health Canada Drug Establishment Licence. The company lists on Nasdaq under OPTH and on the Canadian Securities Exchange under OPTI. Its model centers on regulated treatment supply, clinical research supply and manufacturing.
In June 2026, Optimi reported an export of natural psilocybin biomass and 5 mg capsules to the United Kingdom for a planned Phase 2 study. It also reports regulated supply activity in Australia. Optimi provides current listing, licensing and product information on its company site.
Your investment review should focus on revenue quality, customer concentration, manufacturing utilization, gross margin, regulatory licences and financing. A commercial-stage label does not remove the demand risk that comes with a young regulated market.
9. Red Light Holland
Red Light Holland trades on the Canadian Securities Exchange under TRIP and on OTCQB under TRUFF. The company operates in the legal Dutch psilocybin-truffle market and has pharmaceutical research exposure. In May 2026, it completed the acquisition of Filament Health, adding the PEX010 botanical psilocybin drug candidate, intellectual property and research supply relationships. The Canadian Securities Exchange lists TRIP as active and records the Filament acquisition.
This stock combines consumer sales, natural psilocybin research and several non-psilocybin operations. You should review segment reporting carefully. Legal truffle revenue in the Netherlands and clinical drug development depend on different rules, customers and spending cycles.
10. Bright Minds Biosciences
Bright Minds Biosciences trades under DRUG on Nasdaq and the Canadian Securities Exchange. Its lead candidate, BMB-101, is a selective serotonin 5-HT2C receptor agonist being studied in seizure disorders. In January 2026, the company reported positive topline data from a Phase 2 study in absence seizures and developmental and epileptic encephalopathies. The company’s Phase 2 release reports the data and listing symbols.
DRUG belongs in the broader psychedelic-related set because its platform grew from serotonin-receptor drug research. BMB-101 is not psilocybin and is not a classic hallucinogenic therapy. Your investment thesis therefore centers on neurology drug development.
11. Clearmind Medicine
Clearmind Medicine trades on Nasdaq under CMND. Its lead program, CMND-100, is an oral MEAI-based candidate for alcohol use disorder. The company describes it as non-hallucinogenic. In April 2026, Clearmind said the Phase 1 and 2a study met its primary safety and tolerability endpoint. The study continued to gather pharmacokinetic and early efficacy data. Clearmind reported the primary endpoint in April 2026.
This is an early clinical program with no direct psilocybin exposure. You should give greater weight to full trial data, dose selection, cash runway and later controlled studies than to isolated participant reports.
12. Enveric Biosciences
Enveric Biosciences trades on Nasdaq under ENVB. EB-003 is a preclinical neuroplastogen designed to produce therapeutic receptor activity without hallucinations. The company is carrying out IND-enabling work and lists a pre-IND Food and Drug Administration meeting as the next milestone. Enveric’s investor page describes EB-003 and its current development work.
ENVB sits at the highest-risk end of this list because its lead asset has not entered human testing. Your review should focus on toxicology, manufacturing, regulatory clearance to begin trials, funding needs and share issuance.
13. PharmAla Biotech
PharmAla Biotech trades on the Canadian Securities Exchange under MDMA and on OTCQB under MDXXF. It works on clinical-grade MDMA supply and MDXX-class drug candidates. Its model combines product supply with intellectual property and development programs. PharmAla identifies its listings and operating focus on its investor page.
This company has no psilocybin exposure in the table. You would include it when screening the wider psychedelic medicine sector, especially MDMA research supply. Small-company financing, customer concentration, controlled-substance licences and low trading volume require close review.
Direct Psilocybin Stocks and the Wider Public Set
The label psychedelic stock covers several distinct groups. You can screen them with the following categories.
| Exposure type | Companies in this list | What drives the case |
|---|---|---|
| Direct synthetic psilocybin drug development | Compass Pathways and Incannex Healthcare | Trial results, regulatory review and treatment delivery |
| Direct nature-derived psilocybin drug development | Psyence Biomedical and Red Light Holland through Filament Health | Botanical standardization, trials and regulatory acceptance |
| Natural psilocybin manufacturing and supply | Optimi Health and Red Light Holland | Licences, product quality, orders and regulated-market growth |
| Psilocin-related drug development | Helus Pharma | Phase 3 data, patents and regulatory pathway |
| Other classic psychedelics | Definium Therapeutics, AtaiBeckley and GH Research | LSD, DMT and mebufotenin clinical results |
| Psychedelic-related serotonin and neuroplastogen work | Bright Minds, Clearmind and Enveric | Early clinical or preclinical validation |
| MDMA supply and related development | PharmAla Biotech | Regulated supply, licences and MDXX programs |
If you want the most direct public psilocybin exposure, start your research with CMPS, IXHL, PBM, OPTH and TRIP. Their levels of clinical and commercial maturity vary widely. Compass has the strongest late-stage clinical record. Optimi is primarily a regulated manufacturer. Red Light combines legal truffle sales with botanical drug work. Psyence and Incannex remain in clinical development.
How to Invest in Psilocybin Stocks
You can research and purchase public psilocybin companies through a brokerage that supports the relevant exchange. Nasdaq-listed shares are usually easier for US investors to access. Canadian Securities Exchange and OTCQB securities may require added permissions, foreign-exchange conversion or a broker that supports those venues.
Use a repeatable process before placing any order.
- Define the exposure you want. Choose among a drug developer, natural-product manufacturer, legal truffle operator or multi-program psychedelic company.
- Verify the current legal name, ticker and exchange on the issuer’s investor page and latest regulatory filing. The Definium and Helus changes show why old ticker lists can mislead you.
- Read the latest annual report and quarterly filing. Record cash, short-term investments, quarterly operating cash use, debt, warrants, at-the-market facilities and expected trial spending.
- Build a clinical calendar. Note study phase, enrollment status, primary endpoint, expected readout and the next regulatory interaction.
- Check share liquidity. Thin trading can create wide bid and ask spreads. The Financial Industry Regulatory Authority guide to over-the-counter equities explains how lower liquidity and lighter disclosure can affect OTC securities.
- Review dilution history. Development-stage companies often fund trials by issuing shares, warrants or convertible securities.
- Set risk limits that fit your finances and time horizon. A licensed financial professional can help you assess concentration, tax and loss capacity.
Limit orders can help you control the maximum purchase price in thinly traded shares. They do not guarantee execution. Market orders can fill across a wide spread when volume is low.
What to Check Before You Buy a Psychedelic Stock
Clinical evidence
You should identify the phase and design of each study. An open-label Phase 1 study provides a different level of evidence from a randomized pivotal Phase 3 trial. Check sample size, comparator, primary endpoint, statistical result, safety findings and durability. Company-reported topline data may arrive before peer review and full publication.
Cash runway and dilution
Most clinical-stage psychedelic companies have no approved product revenue. Compare available cash with operating cash use and planned trial costs. Review shelf registrations, at-the-market programs, warrants and recent offerings. A positive clinical result can still be followed by financing that dilutes existing holders.
Regulatory path
Food and Drug Administration designations such as Breakthrough Therapy can allow closer agency interaction. They do not equal approval. For controlled substances, commercial launch may require Drug Enforcement Administration rescheduling after approval. You should also examine the proposed treatment setting, supervision time and practitioner requirements.
Intellectual property
Patents may cover composition, formulation, manufacturing, dosing or methods of use. Read the company’s risk disclosures for patent challenges, licence obligations and expiration dates. Natural psilocybin programs may rely on botanical drug standardization, extraction methods and use patents. The naturally occurring molecule itself has a different ownership profile.
Trading quality
Small psychedelic issuers can have low volume, wide spreads and sharp reactions to press releases. The Securities and Exchange Commission microcap bulletin notes that low trading volume can make shares hard to sell and can increase susceptibility to manipulation. Check the primary listing and do not assume an OTC symbol has the same liquidity as a Nasdaq listing.
Main Risks in Psychedelic Stocks
- Clinical risk remains high. A program can fail on efficacy, safety, durability or trial execution.
- Regulatory review can require new studies, manufacturing work or changes to the care model.
- Financing can dilute your ownership, especially when a company funds multiple large trials.
- Commercial adoption may be limited by long dosing sessions, staff needs, facility capacity, reimbursement and controlled-substance rules.
- Single-asset concentration can make one data release decisive for the company.
- Small-cap and OTC shares can be difficult to enter or exit at the quoted price.
- Patent disputes or narrow claims can weaken expected exclusivity.
- Foreign listings can add currency, tax, settlement and broker-access issues.
Positive Phase 3 endpoints from Compass and Definium show that classic psychedelic programs have reached late-stage clinical testing with measurable outcomes. Investors still need full regulatory review, repeatable safety findings and workable delivery systems before those results can support approved products.
Important 2026 Name and Ticker Changes
Several older psychedelic stock pages now point readers to obsolete symbols.
- Mind Medicine, commonly called MindMed, became Definium Therapeutics. Nasdaq MNMD changed to Nasdaq DFTX in January 2026.
- Cybin began operating as Helus Pharma. NYSE American CYBN moved to Nasdaq HELP in January 2026.
- Atai Life Sciences combined with Beckley Psytech to form AtaiBeckley in November 2025. Nasdaq ATAI remained the symbol.
- Filament Health was acquired by Red Light Holland in May 2026. Its botanical psilocybin work now sits inside CSE TRIP.
Ticker verification should be part of every page update and every investment review. Company names, listings and lead programs can change faster than search results.
How This Page Should Be Maintained
Review this psychedelic stocks list at least once each month and after any major company event. Each update should check the issuer’s investor page, latest securities filing and clinical-trial record.
Revise the table after any of the following events.
- A primary clinical endpoint is reported
- A trial starts, stops or changes phase
- A New Drug Application or comparable filing is submitted
- A regulator approves, rejects or places a hold on a program
- A financing changes cash runway or share count
- A merger, acquisition, name change, ticker change or delisting occurs
- A lead program is paused or discontinued
- A manufacturing licence or commercial supply route changes
Keep a visible review date at the top. Avoid static market prices unless the publishing system can refresh them automatically. Clinical stage, ticker, exchange and source date give readers a more durable reference point.
Frequently Asked Questions
What are the top psychedelic stocks in 2026
The most clinically advanced names include Compass Pathways, Definium Therapeutics, AtaiBeckley, Helus Pharma and GH Research. Compass is the leading direct psilocybin company in this list because two pivotal Phase 3 studies met their primary endpoints and a rolling New Drug Application submission is underway.
Which publicly traded companies have direct psilocybin exposure
Direct exposure in this list includes Compass Pathways, Incannex Healthcare, Psyence Biomedical, Optimi Health and Red Light Holland. Their businesses range from synthetic drug development to nature-derived trials, regulated manufacturing and legal truffle sales.
Is AtaiBeckley a psilocybin stock
AtaiBeckley belongs to the psychedelic medicine sector, though its current lead programs use mebufotenin, DMT and R-MDMA. It has no direct psilocybin program listed here.
Is there an approved psilocybin medicine in the United States
No Food and Drug Administration-approved psilocybin medicine was available as of July 14, 2026. Compass has reported two positive Phase 3 primary endpoints and has started a rolling New Drug Application submission. Approval remains subject to agency review.
Conclusion
Share prices and market values change each trading day. This page focuses on identifiers, compounds, development stages and reported milestones. You should confirm current price, volume and corporate actions through your broker and the relevant exchange before making any decision.
As you review these securities, we at Rose Hill Life Sciences work as a psychedelic research organization focused on the production and research of Psilocybe cubensis. Our Massachusetts-based research sits at the intersection of science and therapeutic integration. Rose Hill does not appear in this public stock table because no public ticker is associated with the organization as of July 14, 2026.
Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.
